Trial Profile

Pivotal Phase 2/3 clinical study of BBP-671 in Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 31 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BBP 671 (Primary)
Indications Pantothenate kinase-associated neurodegeneration
Focus Registrational; Therapeutic Use

Most Recent Events

31 May 2022 New trial record
26 May 2022 According to a BridgeBio Pharma media release, the company expect to initiate this trial in 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com